DFPP plasmapheresis in Turkey: what it is and how double filtration works
DFPP plasmapheresis (double filtration plasmapheresis) is an advanced extracorporeal blood purification technique that selectively removes high-molecular-weight pathogenic substances from the bloodstream. Unlike standard plasma exchange, this method filters blood through two distinct membranes in series. Blood drawn from a vein enters a primary plasma separator, dividing cellular components—red cells, white cells, and platelets—from liquid plasma. The plasma then passes through a secondary fractionator with calibrated microscopic pores that capture targeted macromolecules, such as autoantibodies, immune complexes, cryoglobulins, and low-density lipoproteins, while allowing smaller albumin molecules to return to the body.
Because the secondary membrane retains the patient's own albumin, DFPP eliminates or significantly reduces the need for donor plasma or human albumin replacement infusions. This selective mechanism makes the treatment an established clinical option for severe autoimmune, neurological, and metabolic conditions, often evaluated alongside other regenerative treatments in Turkey. This guide explains how double filtration works, what clinical evidence confirms, what treatments cost compared with the UK, US, and Germany, what to expect during a session, and how to verify hospital standards.
How does the secondary plasma fractionator remove targeted molecules?
The central innovation of DFPP is the secondary hollow-fibre plasma fractionator. In conventional plasmapheresis, plasma is discarded in bulk, carrying away harmful proteins along with essential albumin, immunoglobulins, and coagulation factors. DFPP resolves this by applying sieving coefficients based on molecular weight, typically measured in kiloDaltons (kDa).
Human serum albumin has a molecular weight of approximately 66 kDa, whereas pathogenic molecules are considerably larger: immunoglobulin G (IgG) is around 150 kDa, fibrinogen is about 340 kDa, immunoglobulin M (IgM) is roughly 900 kDa, and low-density lipoprotein (LDL) particles exceed 2,000 kDa. Secondary fractionators feature pore thresholds calibrated between 100 and 150 kDa, blocking larger pathogenic structures while allowing albumin to filter through. As plasma recirculates, retained macromolecules are discharged into a waste container, while the cleaned plasma rejoins cellular blood components and re-enters the venous circulation.
Does DFPP plasmapheresis actually work?
The clinical efficacy of DFPP depends on the condition being treated. Professional organisations such as the American Society for Apheresis (ASFA) and the International Society for Apheresis (ISFA) evaluate apheresis indications according to clinical trial evidence. DFPP has documented efficacy in acute neurological autoimmune flares, including Guillain-Barré syndrome, myasthenia gravis crises, and chronic inflammatory demyelinating polyneuropathy (CIDP), where removing circulating autoantibodies promotes functional nerve and motor recovery.
The procedure is also established for severe familial hypercholesterolemia resistant to medication, systemic vasculitis, and desensitisation before incompatible organ transplantation. In these verified indications, post-treatment laboratory testing shows a 50% to 80% drop in target antibodies or lipids. Conversely, evidence is lacking for commercial claims promoting DFPP as a general "detoxification" or anti-ageing remedy. Randomised clinical trials confirming long-term health benefits for unverified wellness indications do not exist, and reputable hospitals do not market filtration as an anti-ageing therapy.
DFPP plasmapheresis cost in Turkey compared with the UK, US and Germany
The ranges below indicate approximate costs for a standard protocol of two to three DFPP sessions, rather than individual clinic quotes. Total expenditure depends on the patient's diagnosis, the required secondary membrane type, pre-procedure laboratory evaluations, and the level of hospital monitoring. Each licensed facility confirms final pricing in a written quote.
| Country | Approximate cost range (per 2–3 session protocol) |
|---|---|
| Turkey | €3,500 – €8,500 |
| United Kingdom | €8,000 – €18,000 |
| United States | €12,000 – €28,000 |
| Germany | €7,500 – €17,000 |
What changes the dfpp plasmapheresis cost: the precision of the secondary membrane, total plasma volume processed, vascular access requirements (such as a central venous catheter if peripheral veins are small), and inpatient monitoring. A medical package in Turkey typically includes nephrologist consultations, pre-treatment laboratory panels, filtration disposables, nursing care, and local transfers.
DFPP plasmapheresis vs standard TPE and immunoadsorption
Extracorporeal blood purification uses several distinct technologies. Understanding how DFPP compares with standard therapeutic plasma exchange and immunoadsorption helps patients evaluate the appropriate clinical approach.
| Method | Best suited to | Typical limits |
|---|---|---|
| DFPP plasmapheresis | Selective removal of large pathogenic molecules (LDL, IgM, immune complexes) without donor plasma or albumin replacement | Requires specialized dual-filter systems; partial albumin loss can still occur; cannot filter molecules smaller than pore threshold |
| Standard TPE | Acute autoimmune crises (e.g. severe Guillain-Barré, myasthenic crisis, TTP) requiring rapid clearance of all plasma factors | Non-selective; discards all clotting factors; requires substantial donor plasma or albumin replacement with associated allergy risks |
| Immunoadsorption | Targeted antibody removal (e.g. severe dilated cardiomyopathy, pemphigus, transplant desensitisation) using ligand affinity columns | High column expense; limited availability outside specialized academic centres; requires dedicated columns for specific disease targets |
While conventional plasmapheresis removes all plasma indiscriminately, DFPP retains valuable physiological components. However, when highly specific antibody capture is needed without any loss of clotting proteins, immunoadsorption may be recommended where available.
Which medical conditions and clinical indications suit DFPP?
Suitable candidates for double filtration plasmapheresis are individuals with confirmed diagnoses where high-molecular-weight molecules drive disease progression, and who possess adequate vascular access. Recognised indications within clinical therapeutic apheresis include:
- Autoimmune neurological conditions: Myasthenia gravis, Guillain-Barré syndrome, and CIDP during acute exacerbations or treatment-refractory phases.
- Severe metabolic disorders: Homozygous and refractory heterozygous familial hypercholesterolemia where medication fails to reach safe lipid thresholds.
- Autoimmune rheumatologic diseases: Systemic lupus erythematosus with high immune complex loads, severe ANCA-associated vasculitis, and cryoglobulinemic vasculitis.
- Hyperviscosity syndromes: Macroglobulinemia characterized by excessive circulating IgM that impairs microvascular blood flow.
Conversely, DFPP is not appropriate for individuals with unstable hemodynamic status, severe active systemic sepsis, uncorrected coagulopathies, or inadequate vascular access. It is also unsuitable for those seeking general wellness, anti-ageing, or cosmetic outcomes without an underlying medical diagnosis.
What happens during a DFPP session step by step?
A standard DFPP session follows a controlled medical sequence managed by apheresis physicians and dialysis nurses:
- Pre-treatment evaluation: Baseline vital signs, blood counts, electrolyte levels, coagulation times, and serum albumin are checked.
- Vascular access: Two large-bore peripheral cannulas (16–18G) are placed in opposing arms for blood withdrawal and return. If veins are small, a temporary dual-lumen central catheter is inserted under local anaesthesia.
- Anticoagulation: Continuous low-dose heparin or regional citrate is infused into the tubing to prevent clotting within the filters.
- Double filtration: Blood enters the primary separator to yield plasma. The secondary fractionator then isolates and discards pathogenic macromolecules into a waste bag.
- Reinfusion: Cleaned plasma containing the patient's albumin recombines with cellular blood components, passes through a blood warmer, and returns to the patient.
A typical session lasts between two and four hours, processing approximately 1.5 times the patient's calculated plasma volume (around 3 to 4 litres of plasma), with the patient resting comfortably in a clinical recliner.
DFPP plasmapheresis before and after: what results can you realistically expect?
Results from dfpp plasmapheresis before and after are measured through laboratory parameters and symptom stabilization rather than visual changes. Patients should expect measurable physiological improvements rather than cosmetic transformations.
Blood tests immediately following treatment typically confirm a 50% to 75% reduction in circulating autoantibodies, immune complexes, or LDL particles. Patients with hyperviscosity syndromes often note rapid easing of headaches and cognitive sluggishness as microvascular circulation normalises. In autoimmune neurological disorders, improvements in muscle strength and coordination emerge over several days to weeks as inflammatory activity subsides.
However, DFPP clears existing circulating macromolecules; it does not eliminate the underlying cellular mechanisms producing them. Without concurrent medical therapy, such as immunosuppression or lipid-lowering medication, target substances gradually return. Trustworthy specialists never promise permanent cures and ensure filtration is integrated into a comprehensive medical management plan.
Your medical trip to Turkey and DFPP plasmapheresis recovery
A typical protocol for dfpp plasmapheresis in Turkey entails two to three sessions across a five to ten day stay. Maintaining 48 hours between treatments allows vascular access sites to rest, lets fluid compartments stabilise, and provides time to review inter-session blood counts.
Following each session, patients rest in the observation room for 60 to 90 minutes while blood pressure and access sites are monitored. Most people experience mild fatigue, lightheadedness, or slight arm tenderness for the first 24 hours, but can walk gently, eat normally, and relax in their hotel. Strenuous exercise, heavy lifting, and hot baths should be avoided until access sites have fully healed.
Before departure, the medical team conducts a final clinical review, repeating blood counts, coagulation profiles, and protein markers. Patients receive a comprehensive English medical discharge summary documenting processed plasma volumes, filter specifications, and follow-up guidance for their home physician. A scheduled telemedicine check-in three to four weeks later monitors ongoing stability.
Risks, side effects and safety standards in DFPP
Extracorporeal blood filtration carries recognised physiological risks that require careful medical management. International professional bodies, including the International Society for Apheresis, maintain strict clinical safety protocols.
The most common side effect is transient hypotension (low blood pressure) due to fluid shifts within the extracorporeal circuit. Mild hypocalcemia, causing temporary tingling around the mouth or fingertips, can occur when citrate anticoagulation binds calcium; this is quickly resolved with calcium supplementation. Access site bruising and localized soreness occur in a small number of patients.
Because secondary fractionators have molecular weight thresholds, they inevitably remove some clotting proteins, particularly fibrinogen. Consecutive sessions can temporarily lower fibrinogen levels, slightly elevating bleeding risks until levels regenerate over 24 to 48 hours. Rare but serious risks, such as catheter-related infections, allergic reactions to synthetic membranes, or air embolisms, are minimised by using single-use closed circuits in hospitals equipped with advanced intensive care units.
How to choose an apheresis centre in Turkey and clinical red flags
Undergoing therapeutic blood filtration abroad requires verifying clinical standards. DFPP must only be performed in licensed tertiary hospitals with accredited apheresis or nephrology departments, never in outpatient cosmetic clinics or wellness centres.
Ensure your care is led by a board-certified nephrologist or hematologist with formal apheresis training, supported by experienced dialysis nurses. The facility must have on-site diagnostic laboratories offering rapid coagulation and protein testing, alongside an accredited intensive care unit.
Clinical red flags include:
- Clinics marketing DFPP as an anti-ageing or wellness treatment without diagnostic indications.
- Treatments conducted outside licensed hospital facilities without emergency resuscitation support.
- Quotations that do not specify the apheresis device and secondary membrane models.
- Claims of permanent disease cure or zero medical risk.
- Lack of a named supervising specialist or clear post-discharge documentation.
Questions to ask the clinic:
- Which specialist supervises my treatment, and will they be present throughout filtration?
- Which specific secondary membrane filter is chosen for my diagnosis?
- How is vascular access handled if peripheral veins are unsuitable?
- What on-site emergency and intensive care facilities are available?
- Will I receive full laboratory reports comparing pre- and post-filtration levels?
Learn how it works when coordinating clinical care abroad, and request an itemised plan through a free quote from accredited hospital centres in Turkey.
Hospitals with Regenerative Medicine in Turkey
Frequently asked questions
DFPP plasmapheresis, or double filtration plasmapheresis, is an extracorporeal blood purification technique. Blood is drawn from a vein and passed through a primary plasma separator. The separated plasma then passes through a secondary fractionating membrane that discards high-molecular-weight proteins such as autoantibodies, immune complexes and low-density lipoproteins, while returning essential smaller albumin and cellular components to your circulation.
Yes, for defined medical conditions. Clinical studies and international apheresis guidelines support DFPP for severe neuro-immunological disorders, familial hypercholesterolemia, macroglobulinemia and systemic vasculitis. It rapidly lowers circulating antibody titers and inflammatory proteins. However, claims that it acts as a general rejuvenation, detoxification or anti-ageing therapy lack robust clinical trial evidence, and patients should approach unverified wellness indications with caution.
A protocol of two to three DFPP sessions in Turkey typically costs between €3,500 and €8,500, depending on the membrane type, diagnostic testing, hospital monitoring and nursing care required. Equivalent hospital courses in the UK or Germany generally range between €7,500 and €18,000. Each medical facility provides an individualized estimate based on medical records and laboratory requirements.
Before and after results reflect laboratory changes and symptom stabilization rather than physical appearance. Patients with autoimmune neuro-conditions often see reductions in autoantibody concentrations and blood viscosity, leading to stabilized nerve conduction or reduced flare severity. However, because DFPP removes circulating products rather than the underlying cellular source of antibody production, medical therapy remains necessary to prevent recurrence.
Physical recovery from a single DFPP session is typically rapid. Most patients rest for one to two hours in the clinic while blood pressure and fluid levels are monitored, before returning to their hotel. Mild fatigue, dizziness or vascular puncture tenderness may persist for 24 hours. A interval of 48 hours is standard between consecutive treatment sessions.
The filtration process does not cause physical pain while blood circulates through the machine. Mild discomfort is typically limited to the insertion of intravenous cannulas or catheter placement under local anaesthesia. During the session, some patients notice a cool sensation as fluid returns, or temporary lip tingling from the anticoagulant, which is promptly managed with calcium supplementation.
Standard therapeutic plasma exchange discards all plasma non-selectively and requires large replacement infusions of donor plasma or human albumin solution. In contrast, DFPP uses a secondary membrane that isolates and discards only large pathogenic molecules while returning the patient's own albumin. This reduces reliance on donor blood products and significantly lowers the risk of allergic or transfusion-related reactions.
The clearance of circulating antibodies and macromolecules is immediate during treatment, but duration of benefit varies widely. In acute autoimmune crises or relapses, clinical improvements can last several months when paired with immunosuppressive medication. For chronic metabolic conditions, pathogenic molecules gradually replenish over weeks or months, meaning repeated cycles or maintenance pharmaceutical therapy may be required.
DFPP is a recognised medical procedure performed under nephrological or hematological supervision. Common transient side effects include temporary low blood pressure, mild hypocalcemia from anticoagulant use, and puncture site bruising. Serious complications such as clotting, vascular infection or transient depletion of coagulation factors are rare when performed in licensed hospitals adhering to international apheresis safety standards.
Patients travelling to Turkey generally need a stay of five to ten days. This timeframe allows for initial specialist consultation and baseline laboratory tests, two to three filtration sessions spaced 48 hours apart, post-procedure observation and a final medical review before flying home. Complex medical cases may require a longer stay based on physician advice.